Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study

Authors: Rosalind Glasspool[1], Sally Wheelwright[2], Victoria Bolton[2], Lynn Calman[2], Amanda Cummings[2], Beryl Elledge[3], Rebecca Foster[2], Jane Frankland[2], Peter Smith[4], Sebastian Stannard[4], Joshua Turner[2], David Wright[2], Claire Foster[2]

[1]Beatson West of Scotland Cancer Centre and University of Glasgow

[2]Health Sciences, University of Southampton

[3]HORIZONS User Reference Group, University of Southampton

[4]Social Statistics and Demography, University of Southampton

Corresponding author: Rosalind Glasspool, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN. Email ros.glasspool@ggc.scot.nhs.uk.

CRediT author statement

Ros Glasspool: Conceptualization, Writing - Review & Editing. **Sally Wheelwright:** Conceptualization, Data Curation, Writing - Original Draft, Writing - Review & Editing. **Victoria Bolton:** Data Curation, Methodology, Writing – Review & Editing. **Lynn Calman**: Conceptualization, Writing - Review & Editing, Funding acquisition. **Amanda Cummings:** Conceptualization, Data Curation, Writing – Review & Editing, Project Administration. **Beryl Elledge:** Writing - Review & Editing**. Rebecca Foster:** Conceptualization, Data Curation,

Writing – Original Draft, Writing – Review & Editing, Project Administration. **Jane Frankland**: Conceptualization, Writing – review and editing. **Peter Smith:** Writing - Review & Editing, Supervision**,** Funding acquisition. **Sebastian Stannard**: Methodology, Formal Analysis, Writing - Original Draft, Visualization. **Joshua Turner:** Data curation, Project administration, Writing - Original draft, Writing - review & editing. **David Wright:** Writing - Review & Editing. **Claire Foster**: Conceptualization, Writing - Review & Editing, Supervision, Funding acquisition.

Abstract

Objective

Personalised care requires the identification of modifiable risk factors so that interventions can be implemented rapidly following a gynaecological cancer diagnosis. Our objective was to determine what pre-treatment factors are associated with quality of life (QOL) at baseline (pre-treatment) and 12 months.

Methods

1222 women with a confirmed diagnosis of endometrial, ovarian, cervical or vulvar cancer from 82 UK NHS hospitals agreed to complete questionnaires at baseline, three and 12 months. Questionnaires included measures of QOL, health, lifestyle, support and self-management. The primary outcome measure was QOL as measured by Quality of Life in Adult Cancer Survivors (QLACS). Sites provided clinical data at baseline, six and 12 months. Linear regression models were constructed to examine the association between baseline characteristics and QOL outcomes.

Results

QOL declined between baseline and three months, followed by an improvement at 12 months. Baseline (pre-treatment) factors associated with worse QOL at both baseline and 12 months were depression, anxiety, living in a more deprived area and comorbidities which limit daily activities, whereas higher self-efficacy and age of 50+ years were associated with better QOL.

Conclusions

Depression, anxiety and self-efficacy are modifiable risk factors that can impact on QOL. Screening for these, and assessment of whether comorbidities limit daily activities, should be incorporated in a holistic needs assessment and interventions to improve self-efficacy should be made available. Care can then be personalised from the outset to enable all women with a gynaecological cancer the opportunity to have the best QOL.

Highlights

- Quality of life (QOL) declined between diagnosis and three months but improved by 12 months
- Depression, anxiety, living in a more deprived area and comorbidities which limit daily life were associated with worse QOL at baseline and 12 months
- Higher self-efficacy and being older (50+ years) was associated with better QOL at baseline and 12 months

Keywords

Quality of life, endometrial cancer, ovarian cancer, cervical cancer, vulvar cancer

Introduction

An estimated 1.4 million women were diagnosed with cervical, endometrial, ovarian or vulvar cancer world-wide in 2018, representing 15% of all new cancer diagnoses in women [1]. Improvements in detection and treatment have resulted in greater numbers of women living with and beyond gynaecological cancers: for example, in England and Wales, the 10-year age-standardised net survival increased from 55% to 72% for endometrial cancer and from 18% to 35% for ovarian cancer between 1972 and 2017 [2]. As gynaecological cancer survival rates increase, more women are experiencing this as a complex and ongoing disease, with multiple lines of treatment and cycles of recurrence and remission. There is also an increasing number who, although potentially cured, may live with the fear of recurrence and the long-term consequences of treatment [3]. In both scenarios, quality of life (QOL) is likely to be affected in the months and years following a diagnosis.

Globally there is a growing recognition of the need to support people living with and beyond cancer so that the quality of survival can be improved [4]. In the UK, this is operationalised though the NHS Long Term Plan for Cancer which states that “where appropriate every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information and support.” [5]. For women living with a gynaecological cancer, there is a range of significant and long-term physical and psychosocial problems that can impact QOL, both as a result of the cancer itself and its treatment [6-10]. Physical symptoms and issues include those commonly experienced by people living with any cancer, such as pain and fatigue [11], but there are also issues particularly pertinent to this group including the loss of fertility, treatment-induced menopause, sexual dysfunction, bowel and urinary incontinence, and lower limb lymphoedema [6, 8-10, 12, 13]. Commonly reported psychosocial issues include depression

and anxiety, fear of cancer recurrence, as well as issues with body image, relationships and sexuality [7, 12, 14, 15].

Longitudinal assessment of QOL following the diagnosis and treatment of a gynaecological cancer enables us to understand long-term outcomes [6]. Previous studies which have examined QOL prior to treatment and over time, report improvements at follow-up when compared to pre-treatment evaluations, including at three [16] and 12 months [12, 17, 18]. Poor pre-treatment QOL has been associated with post-operative morbidity and hospital re-admission [19]. However, despite several studies describing QOL in women with a gynaecological cancer, few have examined factors associated with it. Understanding determinants of QOL can identify at risk groups, support personalised care during treatment and inform intervention design [14]. Furthermore, recognising who may be at greater risk of poorer outcomes allows follow-up care to be planned appropriately (e.g. the NHS long term plan advocating for risk stratification in the pathway [20]).

The Macmillan HORIZONS Programme [21] was established to assess the impact of cancer and its treatment on people's everyday lives over time, to identify factors associated with recovery and ability to self-manage, and to predict those most likely to need support. This research focus was driven by people affected by cancer [22]. HORIZONS is a national UK prospective longitudinal cohort study comprising three cohorts: breast cancer (women aged under 50 years), non-Hodgkin lymphoma and gynaecological cancers. The gynaecological cohort included 1222 women diagnosed with cervical, endometrial, ovarian or vulvar cancer. All participants were treated with curative intent, recognising that, for some, the chance of cure was low but they may live with disease for several years. HORIZONS involves

collection of a range of clinical, sociodemographic and patient-reported psychosocial data, with outcomes reported from before the start of treatment and at set intervals over a number of years. HORIZONS is informed by a conceptual framework of recovery of health and wellbeing following a diagnosis of cancer and its treatment. [21]. The conceptual framework assumes that personal, environmental, clinical and lifestyle factors will influence how disruptive cancer and its treatment are to an individual's health and well-being. The unique contribution of the HORIZONS conceptual framework is that it combines the perspective of the individual (including factors present prior to cancer treatment), a social network approach and consideration of how people self-manage the demands placed on them by cancer, and their capacity and confidence to do this [21]. The framework is built on empirical evidence and its component parts are well established in the literature and reflect the priorities of people living with and beyond cancer. While other published studies look at quality of life over time, they do not include the range of measures included in HORIZONS, chosen to reflect the dynamic, multifaceted recovery process from before the start of treatment. These features of the HORIZONS Programme make it unique and permit a thorough investigation of the determinants of key outcomes for people living with and beyond cancer, including QOL.

The primary outcome measure was the Quality of Life in Adult Cancer Survivors (QLACS) scale [23]. We also measure QOL using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 [24]. Whilst there is some overlap in the issues covered by these instruments, the QLQ-C30 was originally developed for use in clinical trials and focuses on QOL during treatment, whereas QLACS was developed to assess QOL among cancer survivors so includes issues relevant to QOL beyond treatment. This paper reports on

QOL assessed before starting treatment (baseline), and at three and 12 months post-study entry. We aim to answer the following:

1. What pre-treatment factors are associated with QOL at baseline?
2. What pre-treatment factors are associated with QOL at 12 months?

Based on the conceptual framework [19] and our previous research with colorectal cancer patients [25, 26], we hypothesised that adequate self-efficacy (a person's confidence to achieve particular goals in living with or managing problems associated with illness [27]) would be a key protective factor whilst depression would be a key risk factor for poor QOL.

Method

Participants and procedure

Women with a confirmed diagnosis of endometrial, ovarian, cervical or vulvar cancer who were due to receive primary treatment with curative intent were recruited from 57 NHS sites (82 hospitals) across the UK, between September 2016 and March 2019 [21]. Detailed eligibility criteria are provided in the supplementary material (S1). The stages of included cancer types were limited to those where treatment was given with curative intent, even if the chances of cure were low, in order to assess the longer-term impact of a cancer diagnosis and treatment. FIGO stages IA to IIIA1 for ovarian cancer; IA to IIIC2 for endometrial cancer; IA2 to IIIB for cervical cancer and IA to IIIC for vulvar cancer were included. Women with pre-malignant conditions were excluded. Rare gynaecological tumours were excluded as it was anticipated that insufficient numbers would be recruited to make any meaningful conclusions and a separate focused study may be more appropriate.

Women were consented prior to receiving any treatment, except in cases where a confirmed diagnosis could only be made at the time of surgery. These participants entered the study following a confirmed surgical diagnosis.

Baseline questionnaires were completed by participants at study entry, with follow-up questionnaires sent to participants three and 12 months later, following status checks to ensure this was appropriate. Case Report Forms (CRFs) were completed by NHS site staff at baseline, then six and 12 months later.

Ethical, legal and governance approvals were obtained from the UK Health Research Authority, Health Care Research Wales, Health and Social Care Trusts in Northern Ireland and NHS Research Scotland (REC Ref: 16/NW/0425; IRAS: 202342) and all participants provided written informed consent.

Measures

A range of validated and study-specific outcome measures were selected informed by the study's conceptual framework and following discussions with patient representatives and clinical experts [21] (supplementary material S2). At baseline, participants provided sociodemographic data (including gender, ethnicity, domestic status, household make-up, level of education reached and caring responsibilities), socioeconomic data (including employment, income, state benefits, pension, and accommodation) and lifestyle data (including height, weight, smoking, vaping, alcohol consumption, diet and exercise). Measures of participants' general health status, social support, social integration, health literacy, self-efficacy, resilience and ability to navigate health services were also included.

Physiological, clinical and treatment data were collected from medical records (including age, cancer type, tumour grade, cancer stage and ECOG performance status), and participants' postcodes were used to obtain Indices of Multiple Deprivation.

The primary outcome is QLACS [23], which comprises 47 items grouped into 12 domains, seven of which are generic and five cancer-specific. Each item is rated on a seven-point scale. The Generic Summary Score (QLACS-GSS), based on scores from items in the seven generic domains (cognitive problems, energy/fatigue, negative feelings, pain, positive feelings, sexual function, sexual avoidance), was used in analyses. A lower QLACS-GSS score corresponds to better QOL. We also used the EORTC QLQ-C30 [24] to assess QOL. The EORTC QLQ-C30 comprises 30 items, with most items rated using a four-point scale. A summary score, based on 27 of the 30 items drawn from the five functioning scales (physical, role, cognitive, emotional and social) and eight symptom scales (dyspnoea, pain, fatigue, insomnia, appetite loss, nausea and vomiting, constipation and diarrhoea) [28], was used in the analyses. A higher summary score corresponds to better QOL.

Analysis

T-tests were used to compare QOL scores at each time point. The baseline characteristics of participants who participated at baseline and at 12 months were compared using either Pearson's chi-square tests for categorical measures or t-tests for approximately-normally distributed continuous measures.

Linear regression models were constructed to examine the association between baseline characteristics and QLACS-GSS at baseline (model one), QLQ-C30 summary score at baseline (model two), QLACS-GSS at 12 months (model three), and QLQ-C30 summary score at 12 months (model four). Complete case analysis was applied in each model, i.e. only participants for whom there were no missing data for the baseline characteristics and outcome were included. Residual tests for normality and standard error robustness checks were conducted on each model. We did not adjust for ethnicity owing to the small proportion of participants who were not White British.

A p-value <0.05 was considered statistically significant. All statistical analyses were performed using STATA version 15.1.

Results

Figure 1 shows the flow of participants through the study. All patients presenting with a gynaecological cancer in the timeframe of the study were screened. Reasons for declining to take part included being too busy, not wanting to take part in research, not wanting to complete questionnaires, feeling too anxious or distressed or ill, privacy concerns, and not wanting to be reminded of diagnosis. The demographic profile of people who declined to participate was similar to those who consented. The mean age of those who declined was 63, and of those who consented was 61 and there was no difference in ECOG status. Decliners were slightly more likely to have Stage 3 cancers (15%, as opposed to 10% of consenters) and less likely to have Stage 1 cancers (69%, as opposed to 76% of consenters). We cannot exclude the fact that there could have been differences in baseline and 12 month QOL measures between those that did and did not respond.

239

240

241 *Insert Fig 1 about here*

242

243 The response rate for questionnaires was 80% at baseline and 59% at 12 months. Medical
244 details, collected by CRFs, were received for 100% of those eligible at baseline and 99% at
245 12 months. Most participants were from England (82%), with 13% from Wales, 3% from
246 Scotland and 2% from Northern Ireland. In most cases, participants completed the baseline
247 questionnaire before any treatment, but this was not possible for 28% of participants, as a
248 confirmed diagnosis could only be made at the time of surgery.

249

250 The baseline characteristics of the sample are shown in Table 1. The proportion of
251 participants with each cancer type was consistent with what would be expected in a mixed
252 gynaecological sample, with the majority having endometrial cancer and fewest diagnosed
253 with vulvar cancer. The majority of participants had an ECOG performance status of either 0
254 or 1, indicating good functioning. About half had at least one comorbidity which they
255 reported limited the activities they did on a typical day. Participants lived in areas from all
256 five quintiles of deprivation. Participants were scored as having lower socio-economic status
257 (SES) if they were unemployed or on benefits (excluding child benefit), were renters, or
258 lacked access to a car or to the internet. Just under half of participants reported one or
259 more of these indicators. The majority had a BMI of ≥25 indicating they were overweight or
260 obese. About half reported being physically active and most had never smoked. Most
261 participants lived with others, although less than 20% felt they were fully supported socially.
262 About a third had caring responsibilities. The majority of participants were treated with

surgery (90%), 27% received chemotherapy and 21% radiotherapy. While these treatment figures were not baseline characteristics, they were included in the regression models for completeness. A higher proportion of women aged 50+ years at baseline went on to complete the 12-month questionnaire compared to those who did not (supplementary material, S3). There were no other significant differences in the baseline characteristics of those who responded at 12 months and those that did not (supplementary material, S3 and S4).

Insert Table 1 about here

Quality of life

Summary statistics for the QLACS-GSS and the QLQ-C30 summary score in the first 12 months from diagnosis are shown in Fig 2. On both measures, QOL was significantly worse three months post diagnosis compared with baseline. By 12 months, the QLQ-C30 summary score was significantly better than it was at baseline. Although the QLACS-GSS was lower (indicating better QOL) at 12 months compared with three months, this difference was not quite significant (p=0.057), and it had not returned to baseline levels.

Insert Fig 2 about here.

The results from the four regression models are summarised in Figure 3: only significant variables are shown and, for ease of interpretation, QLACS-GSS axes have been reversed so that bars to the right of zero indicate better QOL for both measures. Final models are presented in the supplementary material (S5- S7).

Model one: association between baseline characteristics and QLACS-GSS at baseline

For the QLACS-GSS, where a higher score corresponds to worse QOL, having either one (4.57 95% CI 1.60, 7.54) or two or more (5.54 95% CI 2.21, 8.87) *limiting comorbidities* and were associated with an increase in QLACS-GSS (worse QOL) at baseline. A one unit increase in *HADS anxiety score* and *HADS depression score* was associated with an increase in QLACS-GSS of 1.05 (95% CI 0.71, 1.39) and 2.79 (95% CI 2.25, 3.32), respectively i.e. worse QOL.

A lower QLACS-GSS (better QOL) at baseline was associated with being *obese* (-4.54 95% CI -7.64, -1.44), being *over the age of 50* (-8.21 95% CI -11.74, -4.69) and being *physically active* (-4.29 95% CI -6.87, -1.72).Better *health status* and greater *self-efficacy* were also associated with better QOL: a one unit increase on the EQ-5D was associated with a decrease in QLACS-GSS score of 0.29 (95% CI -0.36, -0.22) and a one unit increase in self-efficacy was associated with a decrease in QLACS-GSS score of 1.39 (95% CI -2.27, -0.52).

Model two: association between baseline characteristics and QLQ-C30 summary score at baseline

For the QLQ-C30 summary score, where a lower score corresponds to worse QOL, having either one (-2.86 95% CI -4.77, -8.94) or two or more *limiting comorbidities* (-4.49 95% CI -6.64, -2.35), and *cancer stage* two or above (-1.93 95% CI -3.94, 0.08) was associated with lower scores at baseline. A one unit increase in the *HADS anxiety score* and *HADS depression score* was associated with a decrease in QLQ-C30 summary score of 0.36 (95% CI -0.58, -0.13) and 1.92 (95% CI -2.28, -1.57), respectively. Finally, being in the most *deprived* quintile was associated with a decrease in QLQ-C30 summary score of 4.19 (95% CI -6.68, -1.70).

311 Like the QLACS-GSS, higher QLQ-C30 summary scores (better QOL) at baseline were
312 associated with better *health status* (measured by EQ-5D) and *self-efficacy*. A one unit
313 increase in EQ-5D was associated with an increase in QLQ-C30 summary score of 0.16 (95%
314 CI 0.12, 0.21) and a one unit increase in self-efficacy was associated with an increase in QLQ-
315 C30 summary score of 0.81 (95% CI 0.24, 1.38). Being *single, separated or divorced* (2.08
316 95% CI 0.09, -4.08) or being *obese* (2.10 95% CI 0.02, 4.18) were also associated with higher
317 QLQ-C30 summary scores (better QOL).
318
319 *Model three: association between baseline characteristics and QLACS-GSS at 12 months*
320 Having either one (7.25 95% CI 2.11, 12.39) or two or more (13.89 95% CI 8.33, 19.45)
321 *limiting comorbidities* and *tumour grade* three (6.80 95% CI 1.06, 12.54) were associated
322 with a higher score (worse QOL) on the QLACS-GSS at 12 months. Having a lower *SES*
323 (defined as an SES score of two or more (see S2)) was associated with an increase in QLACS-
324 GSS of 8.85 (95% CI 2.07, 15.64) i.e. worse QOL. A one unit increase in *HADS anxiety score*
325 and *HADS depression score* was associated with an increase in QLACS-GSS of 0.62 (95% CI
326 0.04, 1.23) and 1.86 (95% CI 0.92, 2.79), respectively. Two baseline characteristics were
327 associated with a lower QLACS-GSS at 12 months (better QOL): being *over the age of 50* (-
328 11.83 95% CI -18.89, 4.78); and a higher *self-efficacy* score (-2.90 95% CI -4.33, -1.47). Being
329 treated with surgery following cancer diagnosis was also associated with a lower QLACS-GSS
330 at 12 months (better QOL) (-10.21 95% CI -19.09, -1.33).
331
332 *Model four: association between baseline characteristics and QLQ-C30 summary score at 12*
333 *months*

Baseline characteristics that were associated with a lower QLQ-C30 summary score (worse QOL) at 12 months include having either one (-4.60 95% CI -7.26, -1.94) or two or more (-8.54 95% CI -11.41, -5.67) *limiting comorbidities* and being *obese* (-2.84 95% CI -5.64, -0.04). A one unit increase in *HADS depression score* was associated with a decrease in QLQ-C30 summary score of 0.98 (95% CI -1,46, -0.50). Living in the most *deprived* quintile (-4.66 95% CI -8.49, -0.84) and having a lower *SES* (-6.35 95% CI -9.85, -2.84) were both associated with worse QOL at 12 months. Two baseline characteristics were associated with a higher QLQ-C30 summary score (better QOL) at 12 months: a one unit increase in *self-efficacy* was associated with an increase in QLQ-C30 summary score of 1.81 (95% CI 1.07, 2.55). Receiving surgery as a treatment was also associated with an increase in QLQ-C30 summary score (5.78 95% CI 1.19,10.37).

Discussion

HORIZONS is the first prospective cohort study of women diagnosed with a gynaecological cancer, recruited at the point of diagnosis, examining an extensive range of factors and outcomes based on a conceptual framework. While our findings are consistent with other studies that link psychosocial status at diagnosis to QOL in the long term [15], this study is important because it provides evidence to support the delivery of personalised care by identifying who is likely to experience reduced quality of life in the first year following diagnosis and therefore who may need extra support. We have identified pre-treatment factors which are associated with patient-focussed outcomes and are amenable to change which should inform targeted interventions.

For the cohort as a whole, there was a significant reduction in QOL between baseline and three months. The results at 12 months differed slightly depending on which instrument was used to assess QOL. On the QLACS-GSS, although QOL improved between three and 12 months, the difference was not statistically significant and QOL did not return to baseline levels. On the QLQ-C30 summary score, QOL was significantly better at 12 months compared to baseline. Whilst the QLQ-C30 summary score includes some scales which are likely to have long term applicability, it also includes symptoms which are more prevalent during the treatment phase, e.g. nausea and vomiting. The QLACS-GSS was developed specifically to evaluate QOL in longer term survivors and so covers some additional areas, such as sexual functioning. It also frames some items in terms of how bothersome a symptom or issue is rather than whether it is simply present or absent. Although the QLACS-GSS and the QLQ-C30 summary score are both useful QOL tools, it may be that the QLACS-GSS is more sensitive to longer term QOL issues than the QLQ-C30 summary score. These findings serve as a reminder of how QOL tool selection can influence results, the importance of selecting the right instrument depending on purpose and the benefit of using complementary measures.

Clinicians may find it helpful to share the QOL trajectories with patients, so they know what, "on average", to expect, including the dip in QOL at three months. Of course, it is important to explain to patients that there are individuals whose QOL does not follow the same pattern. In addition, the regression models can potentially help clinicians identify women at risk of worse QOL around diagnosis and at 12 months.

At baseline, factors associated with worse QOL for both outcome measures were limiting comorbidities, anxiety and depression. In addition, having a cancer stage >1 or living in the most deprived areas were associated with low QLQ-C30 summary scores. Women with a better self-reported health status and higher self-efficacy had better QOL on both measures, and unexpectedly, so did women who were obese. Previous research in a mixed gynaecological sample has found that obesity is associated with worse QOL [29]. We also found that being single/separated/divorced was associated with a higher QLQ-C30 summary score, being older than 50 years and being physically active were associated with better QOL as assessed by the QLACS-GSS, consistent with a previous longitudinal study which found that younger women with gynaecological cancer reported lower QOL than older women [30]. Some of these findings may be due to the women with endometrial cancer, who made up about two thirds of the total cohort. They were more likely to be older and obese, and they tended to be diagnosed at an earlier stage. Details are shown in the supplementary material, tables S5 and S6.

At 12 months, baseline factors associated with worse QOL on both measures were limiting comorbidities, depression and low SES. In addition, being obese or living in the most deprived areas at baseline were associated with worse QOL (lower QLQ-C30 summary scores) at 12 months. A grade 3 tumour was associated with worse QOL as assessed by the QLACS-GSS at 12 months. The different findings for obesity at baseline and 12 months suggest that obese women tolerated treatment less well. An example of the potential impact of obesity is that just 54% of women with endometrial cancer who were morbidly obese had a laparoscopic hysterectomy compared with 63% of those who were not morbidly obese. Obesity has also been associated with worse QOL in previous studies with

endometrial cancer survivors [31]. High self-efficacy at baseline was associated with better QOL on both measures at 12 months. Being older than 50 years at baseline was associated with better QOL at 12 months as assessed by the QLACS-GSS.

While not a baseline characteristic, we included mode of treatment received within six months of baseline in our regression analysis. We found that having surgery was associated with better QOL at 12 months on both QOL measures. We suggest that the small minority of participants who did not receive surgery may have been less fit than those who did receive surgery, and that this may then be reflected in poorer QOL at 12 months.

Our findings support the hypothesis that self-efficacy is a key protective factor for QOL: it was a significant factor for both measures and at both time points. Women with higher self-efficacy may experience the same challenges as women with lower self-efficacy, but they are more confident about managing and/or resolving those challenges. Our research has previously demonstrated the link between self-efficacy and recovery of health and wellbeing post cancer treatment in people diagnosed with colorectal cancer, and that without intervention, self-efficacy levels do not change [25, 26, 32]. However, self-efficacy is amenable to change, and interventions designed to improve levels of self-efficacy soon after diagnosis could be beneficial in both the short and longer term [33].

Our findings also support the hypothesis that depression is a key risk factor for poor QOL: poor mental health, as assessed by the HADS, was identified as a factor for putting women at risk for poor QOL at baseline and at 12 months. Comorbidities which limit everyday life were also a key risk factor. The most common reported comorbidity which impacts everyday

life was osteoarthritis, followed by depression (as diagnosed by a health professional) and asthma. These conditions are all treatable, as long as they are identified. Our previous research with colorectal cancer patients also found that poor mental health and comorbidities which limit everyday life were associated with poor outcomes [25, 26, 34]. The findings highlight the need for individually tailored care plans that address all modifiable factors for women with complex needs.

Being active was associated with better QOL at baseline as measured by the QLACS-GSS. The influence of lifestyle factors on treatment tolerance and recovery, and the importance of intervening pre-treatment, are now getting increased recognition through the move to include prehabilitation in routine cancer care [35]. Prehabilitation comprises physical and psychological assessments carried out following diagnosis but before the start of acute treatment to "…establish a baseline functional level, identify impairments, and provide interventions that promote physical and psychological health to reduce the incidence and/or severity of future impairments" [36]. While there are few published studies on prehabilitation specifically for gynaecological patients, multimodal prehabilitation programmes specifically for this group are now being developed [37].

Finally, some factors associated with poor QOL, such as low socio-economic status and living in a deprived area, confirm the significant consequences of inequality on health outcomes. In order to deliver personalised care, it is important that clinicians are aware of the impact these factors, and social factors, such as having caring responsibilities, have on outcomes. To help ameliorate the impact of such factors, clinicians can signpost people living with and beyond cancer to agencies to provide the necessary support e.g. advice about financial aid.

The data in this study were collected before the COVID-19 pandemic. Some of the identified risk factors for poor QOL are likely to have been exacerbated by the pandemic and ongoing service changes.

Strengths and Limitations

The strength of this analysis lies in its unique dataset: a large national prospective cohort study, with inclusion/exclusion criteria based solely on diagnostic criteria, meaning the included sample is more representative of the population than clinical trials. However, despite the aim to include representative population sample the ethnic diversity of those included does not reflect that of the UK population. This needs to be addressed in future studies that specifically aim to investigate QOL in different ethnicities and tackle barriers to trial inclusion in these populations. Participants were recruited at diagnosis, which permitted collection of baseline data before the start of treatment. Follow-up of the study cohort is ongoing and will allow further investigation of QOL in the years following diagnosis.

The inclusion of different gynaecological cancers is both a strength – giving a voice to women with rarer diagnoses – but also a limitation as the cancers are different in prognosis and behaviour and there are differences in the patient demographics.

In common with other long-term cohort studies, particularly those which collect large amounts of data directly from participants, there was a reduction in participation levels over time. The response rate to questionnaires at 12 months was 59%; this compares to rates of between 37.7% and 95.6% in other gynaecological cancer cohort studies of varying study

design [12, 14, 18]. Descriptive analyses were used to compare decliners and consenters and also the differences between those who responded at 12 months and those who did not. Decliners and consenters were similar by cancer type, age and ECOG status but differed by cancer stage, with consenters more likely to have Stage 1 cancers. There was no significant difference between responders at 12 months and non-responders regarding ECOG status. However, compared to non-responders at 12 months, responders were more likely to have endometrial cancer and more likely to be aged 61-70 years. Differences between responders and non-responders were controlled for in the regression analysis.

Implications for clinical practice

We recommend that every woman with a diagnosis of gynaecological cancer is screened for depression, anxiety and self-efficacy to manage the consequences of cancer and its treatment soon after diagnosis and offered appropriate psychological support. An assessment of whether comorbidities limit daily activities should also be carried out and a care plan, tailored to the individual, should be developed and reviewed regularly to support the delivery of personalised care. Extra support may be required for younger women, those with low socioeconomic status and those who live in deprived areas, along with additional effort to promote existing interventions and support. These activities could form part of a holistic needs assessment and could be included in a prehabilitation programme.

Conclusion

The results from this unique study have identified poor mental health and comorbidities which limit everyday life as key risk factors for poor QOL at diagnosis and 12 months later. The key protective factor is self-efficacy.

Acknowledgements

We thank all HORIZONS study participants and recruiting NHS trusts and boards; Faye Doyle, Amber Cole, Flavia Bellotto-Trigo, Helen Clegg, Hugh Hiscock, Laura Ingram, Ellysia Mason, Christine May, Joanna Oakley, Rebecca Petch, Bjoern Schukowsky, Nicola Scott, Nicole Tipler, Amber Wilson (study support); Nicole Collaço, Amy Din, Chloe Grimmett, Joanne Haviland, Mubarak Patel, Natalia Permyakova, Samantha Sodergren, Sophia Taylor (researchers). Members of the Tumour Specific Expert Panel for the Gynaecological cancers cohort: Simon Crawford, Beryl Elledge, Alison Farmer, Emma Hudson, Raluca Nagy, Anne Lanceley, Eila Watson. Members of the Programme Management Group: Carl May, Alison Richardson, Anne Rogers and Peter Smith. Members of the Study Advisory Board: Jo Armes, Dany Bell, Andy Davies, Anna Gavin, Rosie Loftus, Iain McNeish, Andy Ness, Alison Richardson, Lesley Smith, Peter Smith, Richard Stephens, Galina Velikova, David Weller and Jessica Corner. Members of the User Reference Group: Elspeth Banks, Beryl Elledge, Angela McCullagh, Tricia Moate, Raluca Nagy, Sue Natt, Jackie Rafferty, Janette Rawlinson, Susan Restorick-Banks, Stephen Scowcroft, Irene Soulsby, Richard Stephens, Lesley Turner. Our funder Macmillan Cancer Support.

References

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68:394-424.

[2] Cancer Research UK. Cancer survival for common cancers. 2021.

[3] McConnell H, White R, Maher J. Categorising cancers to enable tailored care planning through a secondary analysis of cancer registration data in the UK. BMJ open. 2017;7:e016797.

[4] Fallowfield L, Nadler E, Gilloteau I, Greaney M, Gater A, Orsini L, et al. Quality of survival: a new concept framework to assess the quality of prolonged life in cancer. Expert Review of Quality of Life in Cancer Care. 2017;2:225-32.
[5] NHS. The NHS Long Term Plan. 2019.
[6] Greimel E, Thiel I, Peintinger F, Cegnar I, Pongratz E. Prospective Assessment of Quality of Life of Female Cancer Patients. Gynecologic Oncology. 2002;85:140-7.
[7] Linnet Olesen M, Hansson H, Ottesen B, Thranov IR, Thisted LB, Zoffmann V. The psychosocial needs of gynaecological cancer survivors: A framework for the development of a complex intervention. Eur J Oncol Nurs. 2015;19:349-58.
[8] Beesley VL, Alemayehu C, Webb PM. A systematic literature review of the prevalence of and risk factors for supportive care needs among women with gynaecological cancer and their caregivers. Supportive Care in Cancer. 2018;26:701-10.
[9] Zeng YC, Ching SS, Loke AY. Quality of life in cervical cancer survivors: a review of the literature and directions for future research. Oncology nursing forum. 2011;38.
[10] Leitao MM, Zhou QC, Gomez-Hidalgo NR, Iasonos A, Baser R, Mezzancello M, et al. Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecologic Oncology. 2020;156:147-53.
[11] Reb AM, Cope DG. Quality of Life and Supportive Care Needs of Gynecologic Cancer Survivors. West J Nurs Res. 2019;41:1385-406.
[12] Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, et al. Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: A prospective, longitudinal study. Gynecologic Oncology. 2012;124:389-94.
[13] Ferrandina G, Petrillo M, Mantegna G, Fuoco G, Terzano S, Venditti L, et al. Evaluation of quality of life and emotional distress in endometrial cancer patients: A 2-year prospective, longitudinal study. Gynecologic Oncology. 2014;133:518-25.
[14] Hersch J, Juraskova I, Price M, Mullan B. Psychosocial interventions and quality of life in gynaecological cancer patients: a systematic review. Psycho-Oncol. 2009;18:795-810.
[15] Dahl L, Wittrup I, Væggemose U, Petersen LK, Blaakaer J. Life after gynecologic cancer—a review of patients quality of life, needs, and preferences in regard to follow-up. International Journal of Gynecologic Cancer. 2013;23.
[16] Barnaś E, Skręt-Magierło J, Skręt A, Bidziński M. The quality of life of women treated for cervical cancer. Eur J Oncol Nurs. 2012;16:59-63.
[17] Martinez A, Filleron T, Rouanet P, Méeus P, Lambaudie E, Classe JM, et al. Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study. Ann Surg Oncol. 2018;25:535-41.
[18] Jones GL, Jacques RM, Thompson J, Wood HJ, Hughes J, Ledger W, et al. The impact of surgery for vulval cancer upon health-related quality of life and pelvic floor outcomes during the first year of treatment: a longitudinal, mixed methods study. Psycho-oncology. 2016;25:656-62.
[19] Doll KM, Snavely AC, Kalinowski A, Irwin DE, Bensen JT, Bae-Jump V, et al. Preoperative quality of life and surgical outcomes in gynecologic oncology patients: A new predictor of operative risk? Gynecologic Oncology. 2014;133:546-51.
[20] Alfano CM, Jefford M, Maher J, Birken SA, Mayer DK. Building Personalized Cancer Follow-up Care Pathways in the United States: Lessons Learned From Implementation in England, Northern Ireland, and Australia. American Society of Clinical Oncology Educational Book. 2019:625-39.

[21] Foster C, Calman L, Richardson A, May CR, Rogers A, Smith PW. HORIZONS protocol: a UK prospective cohort study to explore recovery of health and well-being in adults diagnosed with cancer. BMJ Open. 2019;9:e029662.
[22] Corner J, Wright D, Hopkinson J, Gunaratnam Y, McDonald JW, Foster C. The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study. Br J Cancer. 2007;96:875-81.
[23] Avis NE, Smith KW, McGraw S, Smith RG, Petronis VM, Carver CS. Assessing Quality of Life in Adult Cancer Survivors (QLACS). Qual Life Res. 2005;14:1007-23.
[24] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.
[25] Foster C, Haviland J, Winter J, Grimmett C, Seymour KC, Batehup L, et al. Pre-Surgery Depression and Confidence to Manage Problems Predict Recovery Trajectories of Health and Wellbeing in the First Two Years following Colorectal Cancer: Results from the CREW Cohort Study. Plos One. 2016;11:18.
[26] Wheelwright S, Permyakova NV, Calman L, Din A, Fenlon D, Richardson A, et al. Does quality of life return to pre-treatment levels five years after curative intent surgery for colorectal cancer? Evidence from the ColoREctal Wellbeing (CREW) study. PLoS One. 2020;15:e0231332.
[27] Bandura A. Social foundations of thought and action: Englewood Cliffs, NJ Prentice Hall.; 1986.
[28] Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. Journal of Clinical Epidemiology. 2016;69:79-88.
[29] Doll KM, Kalinowski AK, Snavely AC, Irwin DE, Bensen JT, Bae-Jump VL, et al. Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity to improve patient-centered outcomes. Cancer. 2015;121:395-402.
[30] Chan YM, Ngan HYS, Li BYG, Yip AMW, Ng TY, Lee PWH, et al. A Longitudinal Study on Quality of Life after Gynecologic Cancer Treatment. Gynecologic Oncology. 2001;83:10-9.
[31] Smits A, Lopes A, Bekkers R, Galaal K. Body mass index and the quality of life of endometrial cancer survivors--a systematic review and meta-analysis. Gynecol Oncol. 2015;137:180-7.
[32] Grimmett C, Haviland J, Winter J, Calman L, Din A, Richardson A, et al. Colorectal cancer patient's self-efficacy for managing illness-related problems in the first 2 years after diagnosis, results from the ColoREctal Well-being (CREW) study. J Cancer Surviv-Res Pract. 2017;11:634-42.
[33] Merluzzi TV, Pustejovsky JE, Philip EJ, Sohl SJ, Berendsen M, Salsman JM. Interventions to enhance self-efficacy in cancer patients: A meta-analysis of randomized controlled trials. Psychooncology. 2019;28:1781-90.
[34] Cummings A, Grimmett C, Calman L, Patel M, Permyakova NV, Winter J, et al. Comorbidities are associated with poorer quality of life and functioning and worse symptoms in the 5 years following colorectal cancer surgery: Results from the ColoREctal Well-being (CREW) cohort study. Psychooncology. 2018;27:2427-35.
[35] Macmillan Cancer Support, Royal College of Anaesthetists, National Institute for Health Research Cancer and Nutrition Collaboration. Prehabilitation for people with cancer. Principles and guidance for prehabilitation within the management and support of people with cancer. 2019.

[36] Silver JK, Baima J. Cancer Prehabilitation: An Opportunity to Decrease Treatment-Related Morbidity, Increase Cancer Treatment Options, and Improve Physical and Psychological Health Outcomes. American Journal of Physical Medicine & Rehabilitation. 2013;92:715-27.
[37] Miralpeix E, Mancebo G, Gayete S, Corcoy M, Sole-Sedeno JM. Role and impact of multimodal prehabilitation for gynecologic oncology patients in an Enhanced Recovery After Surgery (ERAS) program. Int J Gynecol Cancer. 2019;29:1235-43.

Table/Figure Legends

Table 1. Baseline characteristics of recruited participants

Figure 1: Participant flowchart

Figure 2: Quality of life in the first year

Figure 3: Significant baseline characteristics associated with quality of life at baseline and 12 months

S1: Detailed inclusion and exclusion criteria

S2: Data collected at baseline (pre-treatment)

S3: Baseline and 12-month characteristics of participants included in the regression analyses

S4: Mean and standard deviation of baseline characteristics of recruited participants at baseline and 12 months.

S5: Full model of baseline characteristics and QLACS-GSS at baseline and 12 months.

S6: Full model of baseline characteristics and QLQ-C30 summary score at baseline and 12 months.

S7: Significant baseline characteristics that explain quality of life at baseline and 12 months.

Tables

Table 1. Baseline characteristics of recruited participants

	Number	Percent
Age (years) n = 1222		
49 and below	209	17.10
50 +	1013	82.90
Mean age = 61, SD = 13.26		
Cancer type n = 1222		
Ovarian	158	12.93
Endometrial	811	66.37
Cervical	214	17.51
Vulvar	39	3.19
Tumour grade n = 1222		
1	509	41.65
2	301	24.63
3	359	29.38
Unknown	53	3.19
Cancer stage n = 1222		
1	903	73.90
2 or 3	291	23.81
Unknown	28	2.29
ECOG status n = 1222		
0	664	54.34
1	467	38.22
2 +	30	2.45
Unknown	61	4.99
Limiting comorbidities n = 974		

0	477	48.92
1	246	25.33
2 +	251	25.74
Ethnicity n=974		
White British	900	92.40
Other White Background	38	3.90
Asian/Asian British	12	1.23
Other Ethnic Background	15	1.54
Unknown	9	0.92
Domestic status n = 974		
Married/civil partnership	561	57.60
Single/separated/divorced	400	41.07
Unknown	13	1.33
Deprivation index n = 1222		
1st quintile (most deprived)	174	14.24
2nd quintile	271	22.18
3rd quintile	258	21.11
4th quintile	250	20.46
5th quintile (least deprived)	262	21.44
Unknown	7	0.57
Socioeconomic status n = 974		
0 (Higher SES)	544	55.85
1	244	25.05
2 + (Lower SES)	181	18.58
Unknown	5	0.51
Education n = 974		
Higher than compulsory	658	67.56
Compulsory or lower	270	27.72
Unknown	46	4.72

Body Mass Index (kg/m^2) n = 1222		
Underweight (<18.5)	14	1.15
Healthy weight (18.5 -24.9)	234	19.15
Overweight (25 – 29.9)	254	20.79
Obese (30 – 39.9)	367	30.03
Severely obese (40 +)	156	12.77
Unknown	197	16.12
Exercise n = 974		
Active	470	48.25
Inactive	459	47.13
Unknown	45	4.62
Smoking status n = 974		
Never	587	60.27
Current smoker	76	7.80
Ex-smoker	297	30.49
Unknown	14	1.44
Social support n = 974		
Not full support (MOS-SSS<100)	794	81.53
Full support (MOS-SSS=100)	174	17.86
Unknown	6	0.61
Live alone n = 974		
No	775	79.57
Yes	198	20.33
Unknown	1	0.10
Caring for anyone n = 974		
No	649	66.63
Yes	320	32.85
Unknown	5	0.51

654

Supplementary material

S1: Detailed inclusion and exclusion criteria

Included	Excluded	Eligible FIGO stages
Epithelial ovarian cancer including primary peritoneal cancer and fallopian tube cancer Ovarian carcinoma Granulosa tumour of the ovary	Borderline ovarian cancer Germ cell tumour Sarcoma	IA to IIIA1
Endometrial cancer Endometrial carcinosarcoma	Choriocarcinoma Germ cell tumour Sarcoma	IA to IIIC2
Cervical cancer	FIGO stage IAI Cervical carcinoma in situ (CIS) Sarcoma Small cell cancer of the cervix	IA2 to IIIB
Vulvar cancer	Basal cell cancer Melanoma Sarcoma Vulvar intra-epithelial neoplasia (VIN)	IA to IIIC

663 **S2: Data collected at baseline (pre-treatment)**

664

Conceptual Framework Domain	Factor	Measures
Cancer diagnosis and treatment	Cancer Stage	FIGO stage 1, 2 or 3
	Performance Status	Eastern Cooperative Oncology Group (ECOG) Performance status 1, 2, 3 or 4
	Tumour Grade	Grade 1, 2 or 3
	Treatment Start	Date
Consequences of cancer diagnosis and treatment	Quality of Life	EORTC QLQ-C30 [1]
	Psychological consequences (Anxiety & Depression)	Hospital Anxiety and Depression Scale (HADS) [2]
Environmental factors	Caring responsibilities for others	Does participant have caring responsibilities
	Household composition	Does participant live alone
	Social support	Medical Outcomes Study Social Support Survey (MOS-SSS) [3]
Health and wellbeing	General health status	EQ-5D Visual Analogue Scale (EQ5D VAS) [4]
	Quality of life	Quality of Life in Adult Cancer Survivors (QLACS) [5]
Personal factors	Health Literacy	Health Literacy Screening Questions [6
	Resilience	Connor-Davidson Resilience Scale (CD-RISC2) [7]
	Self-efficacy	Self-Efficacy for Managing Chronic Disease Scale (SEMCD) [8]
Pre-existing factors (including Lifestyle)	Age at diagnosis	Age in years
	Area deprivation	Index of Multiple Deprivation (IMD) [9, 10, 11, 12]
	Domestic status	Married or in a partnership vs single, separated or divorced

	Ethnicity	Self-reported ethnicity
	Education (Level achieved)	Highest educational level achieved
	Socio-economic status (SES)	Derived from five binary measures of deprivation: Accommodation type, car or van ownership, employment status, internet access and receipt of benefits (excluding child benefit)*.
	Comorbidities	Number which limit day-to-day activities (Self-reported)
	Alcohol intake	Frequency of alcohol consumption Number of units of alcohol consumed per day
	Body Mass Index (kg/m^2)	Body Mass Index
	Diet	Fruit and vegetable consumption per day
	Exercise	Godin-Shephard Leisure Time Physical Activity Questionnaire [13]
	Smoking status	Current and past smoking habits
Self-management of consequences and aftercare	Health education and self-management	Health Education Impact Questionnaire (heiQ) [14]

665

666 *Socio-economic status (SES): Scores were summed with higher scores reflecting lower SES.

667 Principle component analysis suggested all five variables should be retained and we had

668 good factor loading across all variables. Subsequent analysis found no significant collinearity

669 between SES and the deprivation index.

670

671

672 **S3: Baseline and 12-month characteristics of participants included in the regression**

673 **analyses**

Baseline characteristics	***Sample characteristics at baseline and 12 months***				
	Baseline sample (n =703)		*12m Sample (n =471)*		*Sig.*
	N (%)		*N (%)*		
Age (years)					
49 and below	120	(17.07)	57	(12.10)	
50 +	583	(82.93)	414	(87.90)	*
Domestic status					
married/civil partnership	406	(57.75)	276	(58.60)	
single/separated/divorced	297	(42.25)	195	(41.40)	
Treatment					
before questionnaire	201	(28.59)	135	(28.66)	
after questionnaire	502	(71.41)	336	(71.34)	
Body Mass Index (kg/m^2)					
Healthy weight (18.5 -24.9) or under	165	(23.47)	109	(23.14)	
Overweight (25 – 29.9)	184	(26.17)	132	(28.03)	
Obese (30 +)	354	(50.36)	230	(48.83)	
ECOG status					
0	419	(59.60)	281	(59.66)	
1+	284	(40.40)	190	(40.34)	
Limiting comorbidities					
0	345	(49.08)	247	(52.44)	
1	183	(26.03)	112	(23.78)	
2 +	175	(24.89)	112	(23.78)	
Tumour grade					

1	298	(42.39)	200	(42.46)	
2	195	(27.74)	140	(29.72)	
3	181	(25.75)	112	(23.78)	
Unknown cancer grade	29	(4.13)	19	(4.03)	
Cancer stage					
1	537	(76.39)	366	(77.71)	
2 +	166	(23.61)	105	(22.29)	
Deprivation index					
1st quintile (most deprived)	87	(12.38)	45	(9.55)	
All other quintiles	616	(87.62)	426	(90.45)	
Socioeconomic status					
0 (Higher SES)	425	(60.46)	297	(63.06)	
1	169	(24.04)	109	(23.14)	
2 + (Lower SES)	109	(15.50)	65	(13.8)	
Education					
Higher than compulsory	513	(72.97)	348	(73.89)	
Compulsory or lower	190	(27.03)	123	(26.11)	
Exercise					
Active	370	(52.63)	255	(54.14)	
Inactive	333	(47.37)	216	(45.86)	
Smoking status					
Never	434	(61.74)	301	(63.91)	
Current smoker	52	(7.40)	24	(5.10)	
Ex-smoker	217	(30.87)	146	(31.00)	
MOS support					
No full support	574	(81.65)	389	(82.59)	
Full support (=100)	129	(18.35)	82	(17.41)	

Live alone					
No	565	(80.37)	365	(77.49)	
Yes	138	(19.63)	106	(22.51)	
Caring for anyone					
No	454	(64.58)	322	(68.37)	
Yes	249	(35.42)	149	(31.63)	
Treated with surgery					
No	78	(11.10)	40	(8.49)	
Yes	625	(88.90)	431	(91.51)	
Treated with chemotherapy					
No	516	(73.40)	348	(73.89)	
Yes	187	(26.60)	123	(26.11)	
Treated with radiotherapy					
No	554	(78.81)	372	(78.98)	
Yes	149	(21.19)	99	(21.02)	

674 *** Significant difference was found using t-test (p<0.001)

675 ** Significant difference was found using a Chi-square test (p<0.01) excluding missing

676 * Significant difference was found using a t-test (p<0.05)

677

678

S4. Mean and standard deviation of baseline characteristics of recruited participants at baseline and 12 months.

Baseline characteristics	***Baseline sample (n =729)***		***12m Sample (n =487)***		***Sig.***
	Mean	SD	Mean	SD	
General health (EQ5D_VAS)	71.19	20.69	72.66	20.23	
HADs anxiety	7.75	4.68	7.59	4.57	
HADs depression	4.03	3.63	3.87	3.55	
Fruit and veg consumption	5.58	2.07	5.82	2.00	*
Health literacy score	7.38	1.22	7.21	1.14	
Self-Efficacy (SEMCD)	6.89	2.00	6.96	1.99	
Resilience (CD-RISC2)	6.47	1.46	6.49	1.47	
heiQ health services	3.29	0.51	3.20	0.53	
heiQ social functioning	3.29	0.51	3.29	0.51	

*** Significant difference was found using t-test ($p<0.001$)

** Significant difference was found using a t-test ($p<0.01$)

* Significant difference was found using a t-test ($p<0.05$)

685 **S5. Full model of baseline characteristics and QLACS-GSS at baseline and 12 months.**

686

Baseline characteristics	***Baseline (n =703)***			***12 months (n=471)***		
	Constant	*95% CI*	*Sig.*	*Constant*	*95% CI*	*Sig.*
Age (years)						
≤ 49	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
50 +	-7.77	(-11.55, -3.98)	***	-11.83	(-18.89, -4.78)	**
Domestic status						
married/civil partnership	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
single/separated/divorced	-2.15	(-5.24, 0.94)		-2.27	(-7.68, 3.13)	
Treatment						
before questionnaire	3.32	(0.46, 6.17)	*	-0.20	(-5.17, 4.78)	
after questionnaire	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Body Mass Index (kg/m^2)						
Healthy weight (18.5 -24.9)	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Overweight (25 – 29.9)	-1.74	(-5.21, 1.72)		2.38	(-3.44, 8.20)	
Obese (30 +)	-3.97	(-7.20, 0.74)	*	2.96	(-2.45, 8.38)	
ECOG status						
0	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
1+	0.02	(-2.50, 2.54)		-0.48	(-4.79, 3.83)	
Limiting comorbidities						
0	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
1	4.57	(1.60, 7.54)	**	7.25	(2.11, 12.39)	**
2 +	5.54	2.21, 8.87)	**	13.89	(8.33, 19.45)	***
Tumour grade						
1	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*

2	-0.76	(-3.87, 2.35)		0.23	(-5.03, 5.50)	
3	-1.83	(-5.09, 1.44)		6.80	(1.06, 12.54)	*
Unknown tumour grade	-0.96	(-7.41, 5.50)		-0.48	(-11.69, 10.73)	
Cancer stage						
1	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
2 +	0.48	(-2.64, 3.60)		-2.23	(-7.18, 4.83)	
General health (EQ5D_VAS)	-0.29	(-0.36, -0.22)	***	-0.03	(-0.15, 0.10)	
HADs anxiety	0.99	(0.65, 1.34)	***	0.62	(0.04, 1.23)	*
HADs depression	2.76	(2.21, 3.31)	***	1.86	(0.92, 2.79)	***
Deprivation index						
1st quintile (most deprived)	1.79	(-2.06, 5.65)		3.97	(-3.43, 11.37)	
Other quintiles	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Socioeconomic status						
0 (Higher SES)	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
1	0.88	(-2.12, 3.88)		0.68	(-4.49, 5.85)	
2 + (Lower SES)	1.43	(-2.42, 5.29)		8.85	(2.07, 15.64)	*
Education						
Higher than compulsory	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Compulsory or lower	0.18	(-2.65, 3.01)		3.77	(-1.13, 8.67)	
Exercise						
Inactive	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Active	-4.29	(-6.87, -1.72)	**	-1.29	(-5.69, 3.11)	
Fruit and veg consumption	0.09	(-0.51, 0.70)		0.22	(-0.85, 1.28)	
Smoking status						
Never	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Current smoker	-2.16	(-7.08, 2.76)		5.43	(-4.38, 15.24)	
Ex-smoker	0.62	(-2.07, 3.32)		2.21	(-2.40, 6.81)	

MOS support						
No full support	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Full support (=100)	0.45	(-2.88, 3.78)		-0.17	(-5.91, 5.57)	
Live alone						
No	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Yes	1.38	(-2.48, 5.23)		3.03	(-3.43, 9.49)	
Caring for anyone						
No	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Yes	2.56	(-0.08, 5.19)		-1.13	(-5.72, 3.46)	
Health literacy score	0.36	(-0.67, 1.40)		1.12	(-0.73, 2.97)	
Self-Efficacy (SEMCD)	-1.39	(-2.27, -0.52)	**	-2.90	(-4.33, -1.47)	***
Resilience (CD-RISC2)	-0.57	(-1.62, 0.48)		-0.65	(-2.39, 1.09)	
HEIQ health services	1.58	(-1.60, 4.77)		0.71	(-4.97, 6.39)	
HEIQ social functioning	-2.96	(-6.15, 0.23)		-4.15	(-9.72, 1.42)	
Received surgery						
No	N/A	N/A	N/A	*Ref*	*Ref*	*Ref*
Yes	N/A	N/A	N/A	-10.21	(-19.09, -1.33)	*
Received chemotherapy						
No	N/A	N/A	N/A	*Ref*	*Ref*	*Ref*
Yes	N/A	N/A	N/A	*1.97*	*(-4.46, 8.40)*	
Received radiotherapy						
No	N/A	N/A	N/A	*Ref*	*Ref*	*Ref*
Yes	N/A	N/A	N/A	*-2.47*	*(-8.19, 3.24)*	
Cancer site endometrial						
No	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Yes	-2.24	(-5.47, 1.00)		2.67	(-3.35, 8.70)	
Constant	103.03	(86.24-119.82)	***	102.89	(72.60, 133.18)	***

687 *** Significant difference was found using t-test (p<0.001).

** Significant difference was found using a t-test ($p<0.01$).

* Significant difference was found using a t-test ($p<0.05$).

S6. Full model of baseline characteristics and QLQ-C30 summary score at baseline and 12 months.

Baseline characteristics	***Baseline (n =703)***			***12 months (n=471)***		
	Constant	*95% CI*	*Sig.*	*Constant*	*95% CI*	*Sig.*
Age (years)						
≤ 49	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
50 +	0.56	(-1.89, 3.00)		3.40	(-0.25, 7.04)	
Domestic status						
married/civil partnership	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
single/separated/divorced	2.08	(0.09, 4.08)	*	2.56	(-0.24, 5.35)	
Treatment						
before questionnaire	-5.15	(-7.00, -3.31)	***	1.82	(-0.75, 4.39)	
after questionnaire	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Body Mass Index (kg/m^2)						
Healthy weight (18.5 -24.9)	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Overweight (25 – 29.9)	1.58	(-0.65, 3.82)		-2.91	(-5.92, 0.10)	
Obese (30 +)	2.10	(0.02, 4.18)	*	-2.84	(-5.64, -0.04)	*
ECOG status						
0	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
1+	-0.37	(-1.99, 1.26)		-1.30	(-3.53, 0.93)	
Limiting comorbidities						
0	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
1	-2.86	(-4.77, -0.94)	**	-4.60	(-7.26, -1.94)	**
2 +	-4.49	(-6.64, -2.35)	***	-8.54	(-11.41, -5.67)	***
Tumour grade						
1	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*

2	0.05	(-1.96, 2.05)		2.21	(-0.51, 4.93)	
3	0.03	(-2.07, 2.14)		-1.79	(-4.76, 1.17)	
Unknown tumour grade	-0.29	(-4.45, 3.88)		-1.18	(-6.97, 4.61)	
Cancer stage						
1	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
2 +	-1.93	(-3.94, 0.08)	*	0.42	(-2.82, 3.66)	
General health (EQ5D_VAS)	0.16	(0.12, 0.21)	**	0.02	(-0.04, 0.09)	
HADs anxiety	-0.36	(-0.58, -0.13)	***	-0.09	(-0.40, 0.21)	
HADs depression	-1.92	(-2.28, -1.57)	**	-0.98	(-1.46, -0.50)	***
Deprivation index						
1st quintile (most deprived)	-4.19	(-6.68, -1.70)	**	-4.66	(-8.49, -0.84)	*
Other quintiles	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Socioeconomic status						
0 (Higher SES)	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
1	-0.86	(-2.79, 1.08)		-1.93	(-4.60, 0.74)	
2 + (Lower SES)	-2.45	(-4.94, 0.04)		-6.35	(-9.85, -2.84)	**
Education						
Higher than compulsory	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Compulsory or lower	-0.99	(-2.81, 0.84)		-1.89	(-4.42, 0.64)	
Exercise						
Inactive	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Active	1.30	(-0.36, 2.96)		0.80	(-1.47, 3.07)	
Fruit and veg consumption	0.06	(-0.34, 0.45)		0.20	(-0.35, 0.74)	
Smoking status						
Never	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Current smoker	1.16	(-2.01, 4.33)		-4.94	(-10.01, 0.12)	
Ex-smoker	-1.07	(-2.81, 0.67)		-1.32	(-3.69, 1.06)	

MOS support						
No full support	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Full support (=100)	0.00	(-2.15, 2.15)		2.11	(-0.86, 5.07)	
Live alone						
No	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Yes	-0.71	(-3.20, 1.78)		-1.73	(-5.07, 1.61)	
Caring for anyone						
No	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Yes	-0.48	(-2.18, 1.22)		0.89	(-1.48, 3.26)	
Health literacy score	-0.37	(-1.04, 0.29)		-0.76	(-1.71, 0.20)	
Self-Efficacy (SEMCD)	0.81	(0.24, 1.38)	**	1.81	(1.07, 2.55)	***
Resilience (CD-RISC2)	-0.61	(-1.29, 0.07)		-0.54	(-1.44, 0.36)	
heiQ health services	-1.16	(-3.22, 0.89)		0.61	(-2.32, 3.55)	
heiQ social functioning	-1.46	(-3.52, 0.59)		-0.96	(-3.84, 1.91)	
Received surgery						
No	N/A	N/A	N/A	*Ref*	*Ref*	*Ref*
Yes	N/A	N/A	N/A	5.78	(1.19, 10.37)	*
Received chemotherapy						
No	N/A	N/A	N/A	*Ref*	*Ref*	*Ref*
Yes	N/A	N/A	N/A	-0.46	(-3.78, 2.86)	
Received radiotherapy						
No	N/A	N/A	N/A	*Ref*	*Ref*	*Ref*
Yes	N/A	N/A	N/A	-2.64	(-5.59, 0.32)	
Cancer site - endometrial						
No	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*	*Ref*
Yes	1.12	(-0.97-3.21)		-1.47	(-4.58-1.64)	
Constant	86.57	(75.75, 97.40)	***	77.73	(62.03, 93.43)	***

695 *** Significant difference was found using t-test (p<0.001).

** Significant difference was found using a t-test ($p<0.01$).

* Significant difference was found using a t-test ($p<0.05$).

S7. Significant baseline characteristics that explain quality of life at baseline and 12 months.

Baseline characteristics	*Baseline (n =703)*			*12 months (n=471)*		
	Constant	*95% CI*	*Sig.*	*Constant*	*95% CI*	*Sig.*
QLACS-GSS						
Age (ref: 49 and below)						
50 +	-7.77	(-11.55, -3.98)	***	-11.45	(-18.55, -4.36)	**
Treatment (ref: after questionnaire)						
Before questionnaire	3.32	(0.46, 6.17)	*			
Body Mass Index (kg/m^2) (ref: healthy weight)						
Obese (30 +)	-3.97	(-7.20, 0.74)	*			
Limiting comorbidities (ref: 0)						
1	4.57	(1.60, 7.54)	**	7.25	(2.11, 12.39)	**
2 +	5.54	2.21, 8.87)	**	13.89	(8.33, 19.45)	***
Tumour grade (ref: 1)						
3				6.80	(1.06, 12.54)	*
General health (EQ5D_VAS)	-0.29	(-0.36, -0.22)	***			
HADs anxiety	0.99	(0.65, 1.34)	***	0.62	(0.04, 1.23)	*
HADs depression	2.76	(2.21, 3.31)	***	1.86	(0.92, 2.79)	***
SES (ref: 1)						
2 +				8.85	(2.07, 15.64)	*
Exercise (ref: inactive)						
Active	-4.29	(-6.87, -1.72)	**			

Self-Efficacy (SEMCD)	-1.39	(-2.27, -0.52)	**	-2.90	(-4.33, -1.47)	***
Received surgery (ref: No)						
Yes				-10.21	(-19.09, -1.33)	*
QLQ-C30 summary score						
Domestic status (ref: married/civil partnership)						
Single/separated/divorced	2.08	(0.09, 4.08)	*			
Treatment (ref: after questionnaire)						
Before questionnaire	-5.15	(-7.00, -3.31)	***			
Body Mass Index (kg/m^2) (ref: healthy weight)						
Obese (30 +)	2.10	(0.02, 4.18)	*	-2.84	(-5.64,- 0.04)	*
Limiting comorbidities (ref: 0)						
1	-2.86	(-4.77, -0.94)	**	-4.60	(-7.26, -1.94)	**
2 +	-4.49	(-6.64, -2.35)	***	-8.54	(-11.41, -5.67)	***
Cancer stage (ref: 1)						
2 +	-1.93	(-3.94, -0.08)	*			
General health (EQ5D_VAS)	0.16	(0.12, 0.21)	**			
HADs anxiety	-0.36	(-0.58, -0.13)	***			
HADs depression	-1.92	(-2.28, -1.57)	**	-0.98	(-1.46, -0.50)	***
Deprivation index (ref: All other quintiles)						

1st quintile (most deprived)	-4.19	(-6.68, -1.70)	**	-4.66	(-8.49, -0.84)	*
SES (ref: 1)						
2 +				-6.35	(-9.85, -2.84)	**
Self-Efficacy (SEMCD)	0.81	(0.24, 1.38)	**	1.81	(1.07, 2.55)	***
Received surgery (ref: no)						
Yes				5.78	(1.19, 10.37)	*

*** Significant difference was found using t-test ($p<0.001$).

** Significant difference was found using a t-test ($p<0.01$).

* Significant difference was found using a t-test ($p<0.05$).

Figure 1: Participant flowchart



[a]More CRFs than questionnaires were requested because some people withdrew from questionnaire completion only, status checks do not always apply to CRFs, and there were differences in timing of requests

Figure 2: Quality of life in the first year


Better QOL
Worse QOL
QLACS-GSS
76
77
78
79
80
81
82
83
84
77.81 (27.32); 703
82.56 (29.34); 563
79.06 (29.35): 470
Key: mean (SD); n
0
3
6
9
12
Months since surgery


Better QOL
Worse QOL
QLQC30-GSS
82
80
78
76
74
72
70
76.61 (16.01); 703
73.78 (16.93); 564
80.36 (15.09); 471
Key: mean (SD); n
0
3
6
9
12
Months since surgery

Figure 3: Significant baseline characteristics that are associated with quality of life at baseline and 12 months

Figure 3: Significant baseline characteristics that are associated with quality of life at baseline and 12 months

Model 1: QLACS-GSS at baseline (n=703)



Model 2: QLQ-C30 at baseline (n=703)



Model 3: QLACS-GSS at 12 months (n=471)



Model 4: QLQ-C30 at 12 months (n=471)



Notes: We adjust for completing baseline questionnaires after treatment in all models. Bars to the right of zero indicate better quality of life